Categories Analysis, Health Care

Earnings Preview: Aeterna Zentaris reporting Q4 results on Mar 26

Aeterna Zentaris (AEZS) is scheduled to report its fourth-quarter financial results on March 26, Tuesday, after the regular trading hours. The specialty biopharmaceutical company is expected to post a loss of 19 cents per share, on revenue of $0.25 million, up 40% compared to the same period last year.

It may be noted the company has a remarkable history of beating street estimates.

During the same quarter last year, the company had reported a net loss of 3 cents per share on revenues of $0.9 million.

Image for representation (Photo by Drew Hays on Unsplash)

The company, which specializes in developing endocrine treatments, has seen its stock gain 156% in the trailing 52 weeks. Since the beginning of this year, the stock has increased by 37%, as investors pin their hopes on its diagnostic test Macrilen.

Macrilen is an FDA-approved prescription oral solution to test for adult growth hormone deficiency (AGHD).

The test was out-licensed to Strongbridge Ireland Limited last year for commercialization in Canada and the US. Strongbridge launched it in July last year, and AEterna will get a royalty on the sales.


The test got approval from European authorities earlier this year, and the management is likely to provide more updates on this during the post-earnings conference call.

AEZS has a 12-month average price target of $5.50, suggesting a 34% upside from the last close. The stock has an average rating of Moderate Buy.


Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

V Earnings: Key quarterly highlights from Visa’s Q1 2023 financial results

Visa Inc. (NYSE: V) reported first quarter 2023 earnings results today. Net revenues grew 12% year-over-year to $7.9 billion. GAAP net income rose 6% to $4.2 billion while EPS grew

Earnings: Highlights of Intel’s (INTC) Q4 2022 financial results

Intel Corporation (NASDAQ: INTC) Thursday reported a decline in adjusted earnings and revenues for the fourth quarter. The semiconductor giant also provided guidance for the first quarter of 2023. Fourth-quarter

McCormick (MKC) expects to drive sales growth in 2023 through pricing actions and cost savings

Shares of McCormick & Company Inc. (NYSE: MKC) were down over 5% on Thursday after the company missed expectations on its fourth quarter 2022 results and provided a lower-than-expected earnings

Add Comment
Viewing Highlight